Iacta pharmaceuticals to present at jefferies healthcare conference

Guaynabo, puerto rico--(business wire)--iacta pharmaceuticals, inc. (“iacta”), an innovation leader in ophthalmic therapeutics, today announced that damon burrows, chief executive officer, will present at the jefferies healthcare conference on friday, june 10, 2022 at 8:30 a.m. et. mr. burrows will provide a corporate overview, discuss the company's multiple pharmaceutical assets in development, and provide information on the global accelerator model which is focused on addressing global unmet needs in ophthalmology. the company is led by former allergan executives who have formulated, developed, and launched over thirty new drug products. the jefferies conference will be taking place june 8-10, 2022 in new york city. about iacta pharmaceuticals, inc. iacta is an innovation leader in ophthalmic therapeutics, led by former top executives from one of the leading eye care companies in the world. the company currently has multiple products in development for major market opportunities. ic 800/805 is a novel, non-opioid, dual enkephalinase inhibitor (denki), being studied for the treatment of acute and chronic ocular pain. in addition, iacta’s ic 265, is a syk kinase inhibitor being developed as a potential novel treatment for dry eye disease and other ocular indications. solidified by management’s world-class, proven r&d experience and supported by the company’s ipac subsidiary in asia, iacta is equipped to identify high-quality pharmaceutical technologies, create novel formulations, develop clinic-ready assets, and manage regulatory and intellectual property challenges to accelerate the development and commercialization of innovative nces. for more information, please visit www.iactapharma.com. iacta is a registered trademark of iacta pharmaceuticals, inc., and denki is a trademark licensed to iacta pharmaceuticals, inc. all other trademarks are owned by their respective owners.
SYK Ratings Summary
SYK Quant Ranking